Search

Sudha Rani Vippagunta

from Morris Plains, NJ
Age ~57
Get Report
Also known as:
Sudha R Vippagunta, Sudha Rani T, Sudha T, Sudha Rani A
Phone and address:
34 Emerson Rd, Greystone Park, NJ 07950
Connected to:
Albert E Vipperman, 45Heather A Vipperman, 45Justin Vipperman, 41Leann M Vipperman, 41Rachel R Vipperman, 27Ryan S Vipperman, 27Suresh Vipperla, 49Jessica L Vippolis, 47Arun R Vipra, 52Joliene R Vips, 56

Sudha Vippagunta Phones & Addresses

  • 34 Emerson Rd, Morris Plains, NJ 07950
  • 194 Patriots Rd, Morris Plains, NJ 07950 (973) 359-1279
  • 1530 6Th St, Minneapolis, MN 55454 (612) 333-0441
  • Parsippany, NJ
  • Omaha, NE
  • 2300 Rachel Ter, Pine Brook, NJ 07058

Resumes

Resumes

Sudha Vippagunta Photo 1

Senior Fellow

View page
Location:
1712 Funny Cide Dr, Waxhaw, NC 28173
Industry:
Pharmaceuticals
Work:
Celgene
Senior Director and Compound Leader
Novartis Aug 2011 - Sep 2016
Director and Principal Fellow
Novartis Aug 2011 - Sep 2016
Senior Fellow
Education:
Fairleigh Dickinson University 2015 - 2017
Master of Business Administration, Masters University of Nebraska Medical Center
Doctorates, Doctor of Philosophy, Philosophy
Skills:
Clinical Trials
Pharmaceutical Industry
Oncology
Drug Discovery
Drug Development
Pharmacology
Pharmacokinetics
Hplc
Lifesciences
Project Management
Leadership
Sudha Vippagunta Photo 2

Senior Fellow At Novartis

View page
Position:
Senior Fellow at Novartis
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Novartis
Senior Fellow

Publications

Us Patents

Method Of Making Solid Dispersions Of Highly Crystalline Therapeutic Compounds

View page
US Patent:
8641948, Feb 4, 2014
Filed:
Mar 19, 2012
Appl. No.:
13/423329
Inventors:
Jennifer Snyder - Morris Plains NJ, US
Wei Quin Tong - Basking Ridge NJ, US
Sudha Vippagunta - Morris Plains NJ, US
Assignee:
Novartis AG - Basel
International Classification:
B29C 47/00
B29C 67/24
US Classification:
264211, 2641761, 26421121, 424465
Abstract:
A process for preparing solid dispersions of highly crystalline compounds. The highly crystalline or thermally labile therapeutic compounds are processed in an extruder in combination with a solubilizing agent and optionally a plasticizer. The resulting extrudate features the therapeutic compound in an amorphous state. Particularly useful as the solubilizing agents are surfactants such as poloxamers.

Method Of Making Solid Dispersions Of Highly Crystalline Therapeutic Compounds

View page
US Patent:
20100038816, Feb 18, 2010
Filed:
Aug 14, 2007
Appl. No.:
12/376692
Inventors:
Jennifer Snyder - Morris Plains NJ, US
Sudha Vippagunta - Morris Plains NJ, US
Assignee:
NOVARTIS AG - Basel
International Classification:
B29C 47/00
US Classification:
2641761
Abstract:
A process for preparing solid dispersions of highly crystalline compounds. The highly crystalline or thermally labile therapeutic compounds are processed in an extruder in combination with a solubilizing agent and optionally a plasticizer. The resulting extrudate features the therapeutic compound in an amorphous state. Particularly useful as the solubilizing agents are surfactants such as poloxamers.

Galenical Formulations Of Organic Compounds

View page
US Patent:
20100209480, Aug 19, 2010
Filed:
Sep 24, 2008
Appl. No.:
12/678877
Inventors:
Ralf Altenburger - Eimeldingen, DE
Maggy B. Saunier - Jettingen, FR
Nicole Bargenda - Bad Laer, DE
Michael A. Bock - Freiburg, DE
Sabine Adler - Freiburg, DE
Bruno Buss - Osterholz-Scharmbeck, DE
Catherine Curdy - Riehen, CH
Indrajit Ghosh - Parsippany NJ, US
Stefan Hirsch - Lorrach, DE
Patrice F. Keller - Muespach, FR
Charu Kochhar - Basel, CH
Shoufeng Li - Basking Ridge NJ, US
Nicoletta Loggia - Basel, CH
Amol S. Matharu - Bedminster NJ, US
Julien Taillemite - Huningue, FR
Wei-Qin Tong - Basking Ridge NJ, US
Sudha Vippagunta - Morris Plains NJ, US
Hong Wen - Westfield NJ, US
Marie-Christine Wolf - St. Louis, FR
Jay P. Lakshman - Bridgewater NJ, US
James Kowalski - Belle Mead NJ, US
International Classification:
A61K 31/41
A61K 9/70
A61K 9/48
A61K 9/24
A61K 9/14
A61P 13/12
A61P 9/10
A61P 9/04
A61P 9/12
B29B 9/06
US Classification:
424443, 424451, 424464, 424484, 514381, 264140
Abstract:
The present invention relates to a pharmaceutical oral fixed dose combination comprising

Galenical Formulations Of Organic Compounds

View page
US Patent:
20110165240, Jul 7, 2011
Filed:
Sep 22, 2009
Appl. No.:
13/063955
Inventors:
Stephen Valazza - Matawan NJ, US
Robert F. Wagner - Hillsborough NJ, US
Sudha Vippagunta - Morris Plains NJ, US
International Classification:
A61K 9/28
A61K 31/4422
A61K 9/00
A61K 9/20
A61P 9/10
A61P 9/12
B29C 43/02
B05D 3/00
US Classification:
424474, 514356, 424400, 424464, 264115, 427 214
Abstract:
The present invention relates to a pharmaceutical oral fixed dose combination comprising

Galenical Formulation Comprising Aliskiren And Process For Its Preparation By Melt Extrusion Granulation

View page
US Patent:
20110177166, Jul 21, 2011
Filed:
Sep 23, 2009
Appl. No.:
13/120182
Inventors:
Indrajit Ghosh - Parsippany NJ, US
James Kowalski - Belle Mead NJ, US
Jennifer Snyder - Morris Plains NJ, US
Wei-Qin Tong - Basking Ridge NJ, US
Sudha Vippagunta - Morris Plains NJ, US
International Classification:
A61K 31/41
A61K 31/165
A61K 9/20
A61P 9/12
A61P 9/00
A61P 3/10
B29B 9/02
US Classification:
424465, 514616, 514381, 264141
Abstract:
The present invention relates to galenic formulations wherein the active ingredient aliskiren, preferably, a hemi-fumarate salt thereof, alone or in combination with another active ingredient, is melt-granulated and is present in an amount of more than 20% by weight based on the total weight of the oral dosage form, as well as a process of preparing said solid oral dosage form.

Galenical Formulations Of A Fixed Dose Combination Of Valsartan And Aliskiren

View page
US Patent:
20120009257, Jan 12, 2012
Filed:
Mar 18, 2010
Appl. No.:
13/256454
Inventors:
Indrajit Ghosh - East Hanover NJ, US
Shoufeng Li - East Hanover NJ, US
Wei-Qin Tong - Basking Ridge NJ, US
Sudha Vippagunta - East Hanover NJ, US
Hong Wen - East Hanover NJ, US
International Classification:
A61K 9/20
A61P 13/12
A61P 9/12
A61K 31/41
US Classification:
424464, 514381
Abstract:
The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. Aliskiren is shown to slow the dissolution rate of valsartan and the resultant undesirable gelling of valsartan in the presence of aliskiren is overcome by the use of disintegrants.

Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide

View page
US Patent:
20220249498, Aug 11, 2022
Filed:
Dec 15, 2021
Appl. No.:
17/644473
Inventors:
- Basel, CH
Christin TAUCHMANN - Bad Säckingen, DE
Sudha VIPPAGUNTA - Morris Plains NJ, US
Shau-Fong YEN - Basel, CH
Zhixin ZONG - Franklin Park NJ, US
International Classification:
A61K 31/53
C07D 487/04
A61K 31/517
A61K 31/5377
A61K 9/20
Abstract:
The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.

Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl) Imidazo [1,2-B] [1,2,4] Triazin-2-Yl] Benzamide

View page
US Patent:
20210113569, Apr 22, 2021
Filed:
Feb 13, 2020
Appl. No.:
16/789655
Inventors:
- Basel, CH
Christin Tauchmann - Sankt Florianweg, GE
Shau-Fong Yen - Basel, CH
Sudha Vippagunta - Morris Plains NJ, US
Zhixin Zong - Franklin Park NJ, US
International Classification:
A61K 31/53
C07D 487/04
A61K 31/517
A61K 31/5377
A61K 9/20
Abstract:
The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
Control profile
Sudha Rani Vippagunta from Morris Plains, NJ, age ~57 Get Report